Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions

2000 ◽  
Vol 18 (2) ◽  
pp. 143-147 ◽  
Author(s):  
Allan J. Pantuck ◽  
Amnon Zisman ◽  
Arie S. Belldegrun
Keyword(s):  
Prostate Cancer ◽  
Gene Therapy ◽  
Los Angeles ◽  
University Of California ◽  
Future Directions ◽  
Preliminary Results ◽  
The University

Responsiveness of the University of California-Los Angeles Prostate Cancer Index

Urology ◽  
2010 ◽  
Vol 75 (6) ◽  
pp. 1418-1423 ◽  
Author(s):  
Jonathan Bergman ◽  
Christopher S. Saigal ◽  
Lorna Kwan ◽  
Mark S. Litwin
Keyword(s):  
Prostate Cancer ◽  
Los Angeles ◽  
University Of California ◽  
The University

scholarly journals 665: Salvage Cryosurgical Ablation for Radiorecurrent Prostate Cancer Using Third Generation Cryoneedles: The University of California-Los Angeles Experience

2005 ◽  
Vol 173 (4S) ◽  
pp. 181-181 ◽  
Author(s):  
John S. Lam ◽  
John T. Leppert ◽  
Michelle E. Koski ◽  
Sreenu N. Vemulapalli ◽  
Arie S. Belldegrun
Keyword(s):  
Prostate Cancer ◽  
Los Angeles ◽  
University Of California ◽  
Third Generation ◽  
The University ◽  
Cryosurgical Ablation

Dialogues

2020 ◽  
Vol 2 (3) ◽  
pp. 53-59
Keyword(s):  
Los Angeles ◽  
New Spain ◽  
American Art ◽  
Historical Trauma ◽  
State Building ◽  
University Of California ◽  
Religious Experiences ◽  
Political Space ◽  
California Missions ◽  
The University

The California missions, whose original church spaces and visual programs were produced by Iberian, Mexican, and Native artisans between 1769 and 1823, occupy an ambiguous chronological, geographical, and political space. They occupy lands that have pertained to conflicting territorialities: from Native nations, to New Spain, to Mexico, to the modern multicultural California. The physical and visual landscapes of the missions have been sites of complex and often incongruous religious experiences; historical trauma and romantic vision; Indigenous genocide, exploitation, resistance, and survivance; state building and global enterprise. This Dialogues section brings together critical voices, including especially the voices of California Indian scholars, to interrogate received models for thinking about the art historical legacies of the California missions. Together, the contributing authors move beyond and across borders and promote new decolonial strategies that strive to be responsive to the experience of California Indian communities and nations. This conversation emerges from cross-disciplinary relationships established at a two-day conference, “‘American’ Art and the Legacy of Conquest: Art at California’s Missions in the Global 18th–20th Centuries,” sponsored by the Terra Foundation for American Art and held at the University of California, Los Angeles, in November 2019.

Androgen deprivation therapy and risk of SARS-CoV-2 infection in men with prostate cancer: A University of California (UC) Health System registry study.

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 37-37
Author(s):  
Daniel Kwon ◽  
Rohit Vashisht ◽  
Hala Borno ◽  
Rahul Raj Aggarwal ◽  
Eric Jay Small ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Health System ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Host Cells ◽  
University Of California ◽  
Registry Study ◽  
Medical Centers ◽  
Chi Squared ◽  
The University

37 Background: SARS-CoV-2 entry into host cells is facilitated by the transmembrane protease TMPRSS2. TMPRSS2 expression can be modulated by the androgen receptor. It is unclear whether androgen deprivation therapy (ADT) may partially protect from SARS-CoV-2 infection. Methods: A retrospective registry study of adult men with prostate cancer who underwent testing for SARS-CoV-2 in the UC Health System between February 1, 2020 and October 6, 2020 was performed. The University of California Health COVID Research Data Set (UC CORDS), which includes electronic health data of all patients who underwent testing for SARS-CoV-2 at 5 UC academic medical centers (UC Davis, UC Irvine, UC Los Angeles, UC San Diego, and UC San Francisco) and 12 affiliated hospitals across California, was used. Association of SARS-CoV-2 infection and receipt of ADT (GnRH agonist or antagonist) within 90 days of COVID testing was determined using the Chi-Squared test. Analyses (Chi-Squared or Fisher’s exact tests) were also performed in race/ethnicity subgroups. Results: Overall, 2,948 men with prostate cancer who underwent SARS-CoV-2 testing were identified, of whom 59 (2.0%) tested positive. Of the 2,948 men, 2,124 (72%) were White; 219 (7%) Black or African-American; 182 (6%) Asian or Native Hawaiian/Pacific-Islander; 176 (6%) Other race; and 247 (8%) Unknown race. There were 235 (8%) Hispanic or Latino men. Among the 444 men who received ADT in the entire cohort, 7 (1.6%) tested positive, and among the 2,504 men who did not receive ADT, 52 (2.1%) tested positive (OR 0.76, 95% CI 0.34-1.67, P = 0.49). No statistically significant association between ADT and SARS-CoV-2 positivity was found within race or ethnicity subgroups. Conclusions: No association between the use of ADT and the risk of testing positive for SARS-CoV-2 was identified in this study of a diverse patient population in the University of California Health System medical centers and hospitals. In this setting of an overall low prevalence of SARS-CoV-2 infection, thus far, there is no strong evidence of a protective benefit of ADT.

Sign in / Sign up

Export Citation Format

Share Document